Measles Cases Are Rising. Other Preventable Diseases Could Follow
Apr 17, 2025 6:00 AM Amid an ongoing measles outbreak, the US is also facing a surge in pertussis, or whooping cough. As vaccine rates drop, other diseases could be next. Photo-Illustration: WIRED Staff; Getty Images
As the United States grapples with rising measles cases and outbreaks in several states, another vaccine-preventable disease is quietly spreading throughout the country.
This year, there have been at least 7,599 cases of pertussis, also known as whooping cough, up from 3,473 cases at this time last year, according to the latest tally by the Centers for Disease Control and Prevention. With a record number of parents seeking vaccine exemptions for their children and childhood vaccination rates declining, more outbreaks of measles, pertussis, and other diseases are not just likely, they're inevitable.
'When vaccination rates fall, the first disease you're going to see show up is measles because it's so contagious, but others will follow,' says Ari Brown, a pediatrician in Texas, the epicenter of the current measles outbreak, and a spokesperson for the American Academy of Pediatrics. 'This is a troublesome trend.'
Last year, there were 285 cases of measles for all of 2024. This year, cases have already risen to over 700, and two children have died of the disease. Children have also been dying of whooping cough. In Louisiana, two infants died of the disease in the past six months—the state's first deaths from the illness since 2018—according to a recent statement by the state's surgeon general. In January, South Dakota's department of health announced that a child died due to a co-infection of flu and pertussis. And in February, a local health department in Washington confirmed that a Spokane County child under the age of 5 died of whooping cough—the first in the state since 2011.
A type of bacterial infection, whooping cough is spread through respiratory droplets when an infected person coughs or sneezes. It causes flu-like symptoms and violent, rapid coughing. It's known for the characteristic, high-pitched 'whoop' sound when someone inhales after a coughing fit. The disease is especially dangerous for babies because it can interfere with their breathing.
Nationwide, there were 35,435 cases of whooping cough in 2024, compared with 7,063 in 2023, according to a provisional surveillance report from the CDC. Cases hit a low of 2,116 in 2021 due to social distancing during the Covid-19 pandemic and were still on the rebound in 2023. Yet 2024's numbers far outpaced the 18,617 cases seen in 2019 and 15,609 cases in 2018.
The disease can lead to serious complications, including pneumonia, seizures, brain damage, and death. Infants and young children are particularly at risk. Around a third of infants under six months old who came down with whooping cough in 2024 required hospitalization.
'The crux of the disease is that it's caused by this particular bacteria, Bordetella pertussis , which creates a toxin, and that toxin can be very damaging to our lungs,' says Amy Edwards, associate professor of pediatrics at Case Western Reserve University School of Medicine.
Vaccination is the best way to protect against infection and severe disease. The diphtheria, tetanus, and pertussis, or DTaP, vaccine is given in five doses in infancy and early childhood. Immunity from vaccination and natural infection eventually wanes, and a booster shot is recommended at age 11 or 12 and every 10 years after, including for adults. The CDC advises pregnant people to get a booster during each pregnancy.
Fewer children getting vaccinated also affects adults, who are less likely to be up-to-date on their recommended vaccinations. 'Because a lot of adults don't get boosted, pertussis is going to be one of the earliest vaccine-preventable illnesses that we see in that population,' Edwards says. 'Other vaccine-preventable illnesses will follow if we don't get ahead of it and vaccinate our children.'
For pertussis and measles, high rates of vaccination within communities are needed to make sure everyone is protected from infection and severe disease—some people can't take vaccines for medical reasons, or may have weakened immune systems, and so rely on the collective immunity of everyone else to avoid getting these infections. For measles, 95 percent vaccine coverage is needed for community protection. For pertussis, it's 92 to 94 percent. In many places in the US, vaccination rates have been steadily declining.
The pandemic disrupted many routine health care services, leading to a dip in childhood vaccination rates, and those rates have yet to recover. Confidence in childhood vaccination has plummeted among Republicans, a spillover effect from growing distrust in science as a result of Covid vaccine mandates and rapidly evolving health guidance during the pandemic. More parents are now opting out of vaccinating their children for religious and philosophical reasons.
After a decade of nearly 95 percent of children nationwide receiving all four of the major childhood vaccines—MMR (measles, mumps, and rubella), DTaP, poliovirus, and chickenpox—coverage declined to 93 percent from 2019 to 2023. It fell again, to below 93 percent, during the 2023 to 2024 school year, while the number of exemptions from one or more vaccines among kindergartners grew.
Public health experts worry that childhood vaccination rates could dip further under the current Trump administration with Robert F. Kennedy Jr. at the helm of the US Health and Human Services, which oversees the CDC. Kennedy has long promoted the discredited claim that vaccines cause autism and other anti-vaccine myths. Amid rising measles cases—the highest in the US since 2019—Kennedy has downplayed the threat of the disease.
'We're certainly seeing an increase in the momentum towards the idea of medical freedom or personal choice, and we've heard that messaging reiterated by our current administration,' says Crystal Rommen, director of Louisiana Families for Vaccines, a nonprofit that provides evidence-based information to educate families about the impact of vaccines. 'One message that we're really trying to emphasize to the parents and the other community members across the state is that the MMR vaccine is safe. It's effective,' she says.
Chickenpox is one disease that could come back as a result of declining vaccination rates. Before a vaccine was introduced in 1995, more than 4 million people got chickenpox each year, hospitalizations numbered more than 10,000, and as many as 150 people died, half of them children, according to the CDC.
Diphtheria and tetanus—the other diseases the DTaP vaccine protects against—could be next. While diphtheria has essentially been eradicated in the US, there have been recent cases in Europe. Other vaccine-preventable diseases, such as pneumococcal disease and Haemophilus influenzae type b, or Hib disease, could also rebound.
There's a risk of polio reemergence, too. The US eradicated polio in 1979, and the rest of the world is on the brink of doing so, but USAID cuts by the Trump administration that provide funding for polio vaccination could put that status in jeopardy. If polio cases flare up outside of the US, falling vaccine coverage inside of the country could then leave children vulnerable. 'It depends on how low the vaccination rates get,' Edwards says. 'If people see these outbreaks as a wake-up call and vaccine uptake increases, we really could dodge the rest. But I don't hold out hope for that.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the agreement, each CVAC share will be exchanged for approximately $5.46 worth of BNTX American Depositary Shares (ADS), implying a total equity value of around $1.25 billion for CureVac. The consideration per ADS represents a premium of 55% to CVAC's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025. Subject to the closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. The closing of the transaction, expected in 2025, is based on the fulfillment of certain customary closing conditions and required regulatory approvals. Year to date, shares of CureVac have surged 61% against the industry's 4.8% decline. Image Source: Zacks Investment Research The acquisition of CureVac will help BioNTech enhance its capabilities in advancing investigational mRNA-based cancer immunotherapies by expanding its research, development, manufacturing and commercialization infrastructure. It complements BioNTech's existing strengths in mRNA design, delivery technologies and production. BNTX's Comirnaty is the first approved mRNA-based vaccine for COVID-19, which was developed in collaboration with Pfizer. Strategically, the deal will allow BioNTech to expand beyond its existing oncology pipeline and focus on its newer programs across several tumor types, including key assets like its mRNA-based cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. We remind the investors that earlier in June, BioNTech signed a strategic collaboration agreement with Bristol Myers BMY for the global co-development and co-commercialization of BNTX's BNT327, as monotherapy and in combinations, across numerous solid tumor types. BMY will pay $1.5 billion upfront, with $2 billion in additional payments through 2028 and up to $7.6 billion in milestones. BioNTech and Bristol Myers will equally share costs and profits. BNT327 is in late-stage, potentially registrational clinical studies for two different lung cancer indications. Another phase III study evaluating the candidate in triple-negative breast cancer is planned to start by the end of 2025. Early data show promising synergy in targeting two key cancer pathways. CureVac N.V. price-consensus-chart | CureVac N.V. Quote CureVac currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore IMCR, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 7.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
New York Post
2 hours ago
- New York Post
3 ‘next-level brain hacking' methods biohackers love — a high-tech tool gives you ‘40 years of mediation benefits' in just days
Biohacking isn't just about six-packs and stem cells anymore. Now, longevity junkies are turning inward — using cutting-edge technology and ancient medicine to expand their consciousness, unlock hidden brain power and find inner peace. The Post caught up with Dave Asprey, the self-proclaimed 'father of biohacking,' to learn more about how three trending techniques are helping people rewire their minds. Advertisement 5 Dave Asprey published his sixth book, 'Heavily Meditated,' on May 20, 2025. Robb Report via Getty Images #1: Neurofeedback training 'Neurofeedback is one of the main ways biohackers are reprogramming their brains — and it works,' Asprey told The Post. This noninvasive therapy uses EEG (electroencephalogram) technology to monitor brainwaves in real time. Through audio or visual signals, it helps users recognize their thought patterns and learn how to self-regulate their brain function. Research shows neurofeedback can ease symptoms of neurological and mental health disorders while also boosting cognitive skills such as attention, memory and processing speed. Advertisement 'I've studied with the masters in Nepal and Tibet, taken loads of nootropics, and done plant medicine before it was popular, all to help my brain,' Asprey said. 'However, the one thing that made the biggest difference for me was neurofeedback.' In 2014, Asprey opened a neuroscience center in Washington state, where he runs a five-day intensive called 40 Years of Zen. The program uses custom neurofeedback and other tools to help people upgrade their brains. It promises to boost cognitive function, improve emotional resilience, reduce stress, free up energy, unlock creativity and expand the mind. Advertisement 5 Neurofeedback training can strengthen the brain and help people overcome trauma. The Washington Post via Getty Images 'We're doing next-level brain hacking with neurofeedback to help you get the benefits of 40 years of meditation in a matter of days,' Asprey said. #2: Wearable tech No time or cash for a weeklong brain bootcamp with a $16,000 price tag? Biohackers are also using wearable gadgets to upgrade their minds from the comfort of home. Top of Asprey's list: BrainTap. Advertisement 'This tech combines light and sound to train your brainwaves,' he explained. 'It's definitely worth it.' 5 BrainTap was officially launched in 2014, but the company's roots trace back to the 1970s. BrainTap Technologies The BrainTap headset stimulates specific brain areas to induce a deeply relaxing, meditative state, clearing your mind and easing stress. It requires no special training or experience, and sessions last just 20 to 30 minutes. Memberships run $29.99 a month or $260 a year. Asprey also recommends the Muse headband. The company's S Athena model pairs EEG neurofeedback with functional near-infrared spectroscopy, which tracks blood flow in the brain's prefrontal cortex. 5 The first Muse headband hit the market in 2014. There are now two models available. Muse Muse claims to deliver targeted, effective neurofeedback that sharpens attention, builds mental stamina and promotes deep relaxation. The headset costs $474.99. Advertisement 'This one is worth it as well,' Asprey said. #3: Plant medicine and psychedelics Think: shrooms, ayahuasca, DMT, LSD, ibogaine and ketamine. 'These can be profoundly healing but they're something you should do only after you've tried everything else first,' Asprey cautioned. Among other benefits, substances can supercharge the brain by boosting BDNF and NGF — two proteins essential for the growth, survival and function of neurons. Advertisement 5 Americans are increasingly interested in the potential benefits of psychedelic substances. jozefklopacka – 'Not only do you access altered, valuable states that allow you to understand what's going on in a way that you wouldn't see in everyday reality, but the benefits of those states or anything else you do afterward, like meditation or integration work, will stick better because your brain is more flexible,' Asprey explained. But beware: 'These experiences can leave marks that aren't easy to shake off,' he warned. Asprey stressed the importance of using psychedelics safely — with the right mindset, a secure environment and guidance from an experienced expert, especially if you're new to them. Advertisement He breaks down the 'hierarchy' of plant medicines, psychedelics and their effects on the brain in his new book, 'Heavily Meditated.' The book also dives into ancient traditions and cutting-edge technology that help you hack your brain to speed up or slow down at will, altering both physical and mental states.
New York Post
3 hours ago
- New York Post
Kate Middleton shares a a heartfelt statement after pulling out of Royal Ascot
Kate Middleton revealed why she was absent from Royal Ascot. The Princess of Wales, 43, was expected to attend the annual horse race on Tuesday and Wednesday alongside Prince William, King Charles, Queen Camilla and other royal family members. However, Middleton ended up pulling out and is now addressing how she spent the last few days. In a Friday message, Middleton showed her support during Children's Hospice Week, highlighting the work she has been busy doing. 4 Kate Middleton reveals what she's been focused on the past week. 'No parent expects to hear that their child has a serious health condition that could shorten their life,' the Princess wrote. 'Sadly, this is the reality faced by thousands of families across the country, leaving them heartbroken, fearful of the future and often desperately isolated.' 'Being able to access the support of one of the U.K.'s 54 children's hospices means they don't have to face that future alone,' added Middleton. 'As Patron of East Anglia's Children's Hospices and Tŷ Hafan Children's Hospice in South Wales, I have the immense privilege of seeing for myself the extraordinary work of our children's hospices,' she continued. 'Lifting spirits through laughter, fun and play, as well as listening, holding, caring and sharing, they support children and families through life, death and beyond.' 4 Catherine, Princess of Wales paints the hand of Maggie aged 4 years old whose sibling is being treated at Tŷ Hafan, a children's hospice based in Sully. Getty Images Middleton concluded her message with a note to the public, explaining: 'This Children's Hospice Week,I hope you will join me in celebrating the life-changing work they do and thanking them for the vital care they provide to children and families experiencing the most challenging times.' The Princess has been a stark advocate for kids hospice services since tying the knot with Prince William in 2011. Throughout her overseas tours, Middleton has also visited numerous hospices. In January, the royal visited Tŷ Hafan for the first time in Sully, South Wales, which was built with the support of Princess Diana. 4 Catherine, Duchess of Cambridge visits Waikato Hospice Rainbow Place on April 12, 2014 in Cambridge, New Zealand. Getty Images The director of family well-being services, Tracy Jones, said of the Princess' arrival: 'She immediately gravitated to the children and families — she spent quality time talking to every child and their parents.' 'It's been the most inspiring visit,' Jones continued. 'She crouched down and was straightaway on the level of the children. If they were in a wheelchair, she crouched at that level. If they were on the floor, she would be at the level,' she continues. 'We were seriously impressed with how she could stay in a crouch, as it's not that comfortable!' 4 Prince William, Prince of Wales (Colonel of the Welsh Guards), Prince Louis of Wales, Prince George of Wales, Catherine, Princess of Wales and Princess Charlotte of Wales watch an RAF flypast from the balcony of Buckingham Palace after attending Trooping The Colour 2025 on June 14, 2025 in London, England. Getty Images 'She instinctively seemed to know where to touch a child that was going to provide the connection, but not cause any distress or startle a child. She was looking at the children, even if she was talking to the parent. It's what we do, as we're used to working with children who are nonverbal.' Despite missing out on Royal Ascot, Middleton joined her husband and their three kids Prince George, 11, Princess Charlotte, 10, and Prince Louis, 7, for the annual Trooping the Colour in London on Saturday.
